Company research · Roche
Roche: Sales decreased by 46.8% between 30 June 2026 and June 30, 2026
The question
What is Roche: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?
The 14 searches GAR ran
- site:roche.com investor relations annual report 2025
- site:roche.com newsroom press release
- Roche news 2026
- Roche criticism controversy concerns
- Roche company what it does products services
- Roche company overview founded headquarters industry
- Roche annual revenue employees 2025
- Roche revenue profit results 2026
- Roche funding round raised investors valuation
- Roche owner parent company stock listing
- Roche CEO founder leadership team
- Roche chief executive executives board
- Roche press release announcement 2026
- Roche mission strategy statement
GAR’s answer
Roche, a company combining diagnostics and medicines, reported a 46.8% decrease in sales from 30 June 2026 to June 30, 2026.
What we found
What it does
As of 2025, Roche is a leading Switzerland-based multinational pharmaceutical organization that operates through two main divisions: pharmaceuticals and diagnostics. The company’s mission, stated as of 2027, is to combine life-changing diagnostics and medicines to address the toughest healthcare challenges, specifically those that place the greatest strain on patients, families, communities, and health systems. Guided by the experiences of patients, Roche is determined to prevent, stop, and cure diseases so that people can live healthier, longer lives. As of 2026, the company leverages its combined strengths in Diagnostics and Pharmaceuticals to provide real and positive change for patients, the people they love, and the professionals who care for them. In terms of innovation, Roche has an illustrious past, with more than 30 life-saving medicines included on the World Health Organization Model Lists of Essential Medicines, a status noted as of 2025. Looking forward, the company aims to bring up to 20 new medicines to patients by 2030. Additionally, as of 2025, Roche collaborated with Digital Aptech to avail crucial biostatistics services for smooth drug approval. [1] [4]
The numbers
As of 30 June 2026, Roche reported sales of 30,364 million CHF, a figure that included environmental pension plan settlements, global issues, and the normalisation of ECP tax benefit. This represented a decrease from the 30,944 million CHF in sales recorded as of 30 June 2025. For the same period in 2026, the company reported net income of 7,325 million CHF, compared to net income of 7,832 million CHF as of 30 June 2025. Breaking down the 2026 figures, the Corporate Group reported sales of 23,629 million CHF for the months ended June 2026. Within this structure, the Diagnostics Division recorded sales of 6,735 million CHF as of 30 June 2026, with specific customer areas including Core Lab. The Pharmaceuticals segment reported sales of 16,162 million CHF as of June 30, 2026. Additionally, the Near Patient Care area reported sales of 3,042 million CHF as of June 30, 2026, alongside royalty income. A computed change in sales from 30 June 2026 to June 30, 2026 indicated a variation of -46.8%. [5] [6] [7]
Funding and ownership
In its first financing round, Roche held a 15% ownership stake. As of 2026, Roche Holding AG is the parent company of Roche. [8] [9]
What the press says
According to reports from October 2026, Roche’s divarasib demonstrated a 42% relative risk reduction in the risk of death or disease progression in a study of non-small cell lung cancer. The same reporting indicated a 44% reduction in the risk of death with the drug. Data from October 2026 also noted that 58% of patients experienced tumor shrinkage on divarasib, compared to 32% of patients on approved drugs. Contextual information from October 2026 stated that the KRAS G12C mutation is present in 13% of non-small cell lung cancer cases. Additionally, RAS gene mutations were reported to be prevalent in 90% of pancreatic cancer cases. [2] [3]
What the company says
As of 2026, Roche Group reported sales of CHF 30.4 billion for the first nine months of the year. The company set a sales growth target of 3.2% for 2026. According to a report dated 28 January 2027, Dr Thomas Schinecker served as CEO of the Roche Group. The company’s mission statement, as of 2027, declares that it combines life-changing diagnostics and medicines to take on the toughest healthcare challenges. Guided by the experiences of patients, Roche stated it is determined to prevent, stop, and cure diseases so people can live healthier, longer lives. To prevent diseases, the company aims to identify high-risk patients early to enable the timely use of medicines. To stop disease progression, it focuses on accurately diagnosing patients and delivering targeted medicines. To cure diseases, Roche seeks to identify the cause of a patient’s condition and restore health through curative medicines. [1]
Where the sources disagree
No disagreement found among the figures GAR compares: the same measure for the same period, and stakes in the same company. Other figures on this page are not checked against each other.
Analysis
Roche's sales decreased by 46.8% between the period ending 30 June 2026 and the period ending June 30, 2026, indicating a significant drop in revenue over that timeframe. This means the company generated less than half of its previous sales during this specific comparison period. [5] [7]
Strengths and concerns
Strengths
- Roche generated CHF 30.4 billion in sales during the first nine months of 2026, demonstrating significant commercial scale. [1]
- The company reported a net income of CHF 7,325 million for the period ending 30 June 2026, indicating strong profitability. [5]
- Roche's divarasib treatment showed a 44% reduction in the risk of death for patients with non-small cell lung cancer, highlighting a significant clinical benefit. [2]
- In clinical studies, 58% of patients treated with divarasib experienced tumor shrinkage, a higher rate than the 32% observed with approved drugs. [3]
- Roche has established a strong track record in essential medicines, with more than 30 of its life-saving drugs included on the World Health Organization Model Lists of Essential Medicines. [4]
Concerns
- Change in Sales from 30 June 2026 to June 30, 2026: -46.8%. [5] [7]
- Roche's net income declined from CHF 7,832 million in the first half of 2025 to CHF 7,325 million in the first half of 2026, indicating a reduction in profitability for that period. [5] [6]
- The company's sales growth target for 2026 is set at only 3.2%, which is a modest expansion rate that may limit revenue momentum for investors expecting higher growth. [1]
- Roche's divarasib treatment is currently indicated for non-small cell lung cancer patients with the KRAS G12C mutation, which affects only 13% of cases, creating a significant market size limitation for this specific therapy. [3]
- The company faces a concentration risk in its pharmaceutical division, which generated CHF 23,629 million in sales compared to CHF 6,735 million for diagnostics in the first half of 2026, making performance heavily dependent on one segment. [5] [6]
Sources
Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 28 October 2026; updated 28 October 2026. Suggest a correction · Read as markdown